1489 related articles for article (PubMed ID: 29867230)
1. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
McDermott DF; Huseni MA; Atkins MB; Motzer RJ; Rini BI; Escudier B; Fong L; Joseph RW; Pal SK; Reeves JA; Sznol M; Hainsworth J; Rathmell WK; Stadler WM; Hutson T; Gore ME; Ravaud A; Bracarda S; Suárez C; Danielli R; Gruenwald V; Choueiri TK; Nickles D; Jhunjhunwala S; Piault-Louis E; Thobhani A; Qiu J; Chen DS; Hegde PS; Schiff C; Fine GD; Powles T
Nat Med; 2018 Jun; 24(6):749-757. PubMed ID: 29867230
[TBL] [Abstract][Full Text] [Related]
2. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
Motzer RJ; Powles T; Atkins MB; Escudier B; McDermott DF; Alekseev BY; Lee JL; Suarez C; Stroyakovskiy D; De Giorgi U; Donskov F; Mellado B; Banchereau R; Hamidi H; Khan O; Craine V; Huseni M; Flinn N; Dubey S; Rini BI
JAMA Oncol; 2022 Feb; 8(2):275-280. PubMed ID: 34940781
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Rini BI; Powles T; Atkins MB; Escudier B; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Lee JL; Hawkins R; Ravaud A; Alekseev B; Staehler M; Uemura M; De Giorgi U; Mellado B; Porta C; Melichar B; Gurney H; Bedke J; Choueiri TK; Parnis F; Khaznadar T; Thobhani A; Li S; Piault-Louis E; Frantz G; Huseni M; Schiff C; Green MC; Motzer RJ;
Lancet; 2019 Jun; 393(10189):2404-2415. PubMed ID: 31079938
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
Powles T; Atkins MB; Escudier B; Motzer RJ; Rini BI; Fong L; Joseph RW; Pal SK; Sznol M; Hainsworth J; Stadler WM; Hutson TE; Ravaud A; Bracarda S; Suarez C; Choueiri TK; Reeves J; Cohn A; Ding B; Leng N; Hashimoto K; Huseni M; Schiff C; McDermott DF
Eur Urol; 2021 May; 79(5):665-673. PubMed ID: 33678522
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
Pal SK; McDermott DF; Atkins MB; Escudier B; Rini BI; Motzer RJ; Fong L; Joseph RW; Oudard S; Ravaud A; Bracarda S; Suárez C; Lam ET; Choueiri TK; Ding B; Quach C; Hashimoto K; Schiff C; Piault-Louis E; Powles T
BJU Int; 2020 Jul; 126(1):73-82. PubMed ID: 32233107
[TBL] [Abstract][Full Text] [Related]
6. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Motzer RJ; Banchereau R; Hamidi H; Powles T; McDermott D; Atkins MB; Escudier B; Liu LF; Leng N; Abbas AR; Fan J; Koeppen H; Lin J; Carroll S; Hashimoto K; Mariathasan S; Green M; Tayama D; Hegde PS; Schiff C; Huseni MA; Rini B
Cancer Cell; 2020 Dec; 38(6):803-817.e4. PubMed ID: 33157048
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.
Rini BI; Motzer RJ; Powles T; McDermott DF; Escudier B; Donskov F; Hawkins R; Bracarda S; Bedke J; De Giorgi U; Porta C; Ravaud A; Parnis F; Grande E; Zhang W; Huseni M; Carroll S; Sufan R; Schiff C; Atkins MB
Eur Urol; 2021 May; 79(5):659-662. PubMed ID: 32654802
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Wallin JJ; Bendell JC; Funke R; Sznol M; Korski K; Jones S; Hernandez G; Mier J; He X; Hodi FS; Denker M; Leveque V; Cañamero M; Babitski G; Koeppen H; Ziai J; Sharma N; Gaire F; Chen DS; Waterkamp D; Hegde PS; McDermott DF
Nat Commun; 2016 Aug; 7():12624. PubMed ID: 27571927
[TBL] [Abstract][Full Text] [Related]
9. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab
Atkins MB; Rini BI; Motzer RJ; Powles T; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Gurney H; Oudard S; Uemura M; Lam ET; Grüllich C; Quach C; Carroll S; Ding B; Zhu QC; Piault-Louis E; Schiff C; Escudier B
Clin Cancer Res; 2020 Jun; 26(11):2506-2514. PubMed ID: 32127394
[TBL] [Abstract][Full Text] [Related]
10. Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
Uemura M; Tomita Y; Miyake H; Hatakeyama S; Kanayama HO; Numakura K; Takagi T; Kato T; Eto M; Obara W; Uemura H; Choueiri TK; Motzer RJ; Fujii Y; Kamei Y; Umeyama Y; di Pietro A; Oya M
Cancer Sci; 2020 Mar; 111(3):907-923. PubMed ID: 31883418
[TBL] [Abstract][Full Text] [Related]
11. Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma.
Lanillos J; Santos M; Valdivia C; Mora A; Rodríguez-Antona C
Eur Urol; 2022 Sep; 82(3):334-335. PubMed ID: 35688666
[No Abstract] [Full Text] [Related]
12. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
13. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
[TBL] [Abstract][Full Text] [Related]
14. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
18. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Alam MU; Jazayeri SB; Gautam S; Norez D; Kumar J; Tanneru K; Nguyen S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Am J Clin Oncol; 2020 Jul; 43(7):477-483. PubMed ID: 32251121
[TBL] [Abstract][Full Text] [Related]
20. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
Rivera F; Karthaus M; Hecht JR; Sevilla I; Forget F; Fasola G; Canon JL; Guan X; Demonty G; Schwartzberg LS
Int J Colorectal Dis; 2017 Aug; 32(8):1179-1190. PubMed ID: 28424871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
